The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.
The SBIR grant could be worth as much as $2.3 million and will help PapGene develop and commercialize its proprietary ovarian and endometrial cancer detection test.
The company believes it can make oligonucleotide synthesis faster and cheaper than currently available methods, and plans to launch a platform in the next year.
The company is developing a cloud-based platform for the detection, quantification, and interpretation of alternative splicing variation from NGS data.
